CDXS Codexis, Inc.
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 What Needs To Be True To Buy Twist Bioscience Stock Now? A $10,000 holding in Twist Bioscience (TWST) a year ago is worth about $66,600 today. The same sum in the S&P 500 would be worth about $11,700. The company sells made-to-order DNA to drug makers and research labs. Its sales grow fast, but it still loses money. The price now counts on that growth lasting and the losses ending. How much has to go right for that price to hold. | ||
 Codexis (CDXS) Q2 2026 Earnings Call Transcript Product revenue surged 78% YoY as launches drive margin expansion and extend cash runway. | ||
 Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock? Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | ||
Codexis Inc (CDXS) (Q2 2026) Earnings Call Highlights: Biocatalysis Growth and ECO Synthesis ... Codexis Inc (CDXS) reports improved gross margins and advances ECO Synthesis platform despite slight revenue dip, with cash runway extended through 2028. | ||
 Codexis, Inc. Q2 2026 Earnings Call Summary Moby summary of Codexis, Inc.'s Q2 2026 earnings call | ||
 Codexis Q2 Earnings Call Highlights Codexis (NASDAQ:CDXS) reported second-quarter 2026 revenue of $14.9 million, compared with $15.3 million in the prior-year period, as the company highlighted improved performance in its biocatalytic enzyme business and continued development of its ECO Synthesis platform for siRNA manufacturing. Net | ||
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates Codexis (CDXS) delivered earnings and revenue surprises of +23.53% and +17.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates ANI (ANIP) delivered earnings and revenue surprises of +9.95% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +21.50% and +18.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates AC Immune (ACIU) delivered earnings and revenue surprises of +113.64% and +1,812.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||